Document Type: Original Article


1 Dept. of Periodontology, Faculty of Dentistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

2 Dept. of Clinical Science, Science and Research Branch, Islamic Azad University, Tehran, Iran.

3 Head of Department of Pathology, Faculty of Specialized Veterinary Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran.

4 Postgraduate Student of Pediatric Dentistry, Dental Research Center, Dept. of Pediatric Dentistry, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran.


Statement of the Problem: Alveolar bone resorption due to periodontal disease is common and generally irreversible. It impairs mastication and causes esthetic problems for patients.Bisphosphonates are the most commonly used antiresorptive agents for bone diseases.
Purpose: Considering the risk of bisphosphonate-related osteonecrosis of the jaw, this study aimed to assess the effect of 2% risedronate gel on calvarial bone defects in rabbits.
Materials and Method: In this animal study, 8 mm critical size defect were created in the calvaria of 20 New Zealand white rabbits. In group 1 (n=10), 2% risedronate gel was applied into the right side defect while the left side defect remained empty and served as control. In group 2 (n=10), placebo gel was applied into the right side defect, while the left side defect remained empty and served as control. Five rabbits in each group were sacrificed at 1 and the remaining five at 2 months post-operatively and tissue samples were collected for histomorphometric analysis. Histomorphometric assessments included bone fill, degree of inflammation, number of osteoblasts, number of osteoclasts and foreign body reaction at the site. Data were statistically analysed using SPSS version 25 via the Dunn test and Kruskal-Wallis test.
Results: No bone remodeling was noted in any group at 1 month. The risedronate group showed significantly higher bone fill than the other groups after 2 months (p = 0.016). At 2 months, the number of osteoblasts was significantly higher in the risedronate group (p < 0.05). The groups were not significantly different in terms of inflammation score at 1 (p = 0.31) or 2 (p =0.69) months. Foreign body reaction was not observed in any group at any time point. No osteoclast was detected in any group at any time point.
Conclusion: Risedronate gel showed superior efficacy with regard to regeneration of rabbit calvarial bone defects compared to the placebo and control groups. 


[1]  Newman MG, Takei HT, Klokkevold PR, Carranza FA. Carranza's clinical periodontology. 13th ed. St. Louis: Saunder Elsevier; 2019. p. 577-583.

[2]  Toker H, Ozdemir H, Ozer H, Eren K. A comparative evaluation of the systemic and local alendronate treatment in synthetic bone graft: a histologic and histomorphometric study in a rat calvarial defect model. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 114: S146-S152.

[3]  Reich W, Bilkenroth U, Schubert J, Wickenhauser C, Eckert AW. Surgical treatment of bisphosphonate-associated osteonecrosis: Prognostic score and long-term results. J Craniomaxillofac Surg. 2015; 43: 1809-1822.

[4]  Vescovi P, Campisi G, Fusco V, Mergoni G, Manfredi M, Merigo E, et al. Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol. 2011; 47: 191-194.

[5]  Dannemann C, Gratz KW, Riener MO, Zwahlen RA. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone. 2007; 40: 828-834.

[6]  Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010; 136: 1117-1124.

[7]  Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61: 1115-1117.

[8]  Gong T, Wang Z, Zhang Y, Sun C, Yang Q, Troczynski T, et al. Preparation, characterization, release kinetics, and in vitro cytotoxicity of calcium silicate cement as a risedronate delivery system. J Biomed Mater Res A. 2014; 102: 2295-2304.

[9]  Kwak HB, Kim JY, Kim KJ, Choi MK, Kim JJ, Kim KM, et al. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Biol Pharm Bull. 2009; 32: 1193-1198.

[10]          Moreau MF, Guillet C, Massin P, Chevalier S, Gascan H, Baslé MF, et al. Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol. 2007; 73: 718-723.

[11]          Santamaria M*Jr, Fracalossi AC, Consolaro MF, Consolaro A. Influence of bisphosphonates on alveolar bone density: a histomorphometric analysis. Braz Oral Res. 2010; 24: 309-315.

[12]          Van*Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 1999; 264: 108-111.

[13]          Cetinkaya BO, Keles GC, Ayas B, Gurgor P. Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats. J Periodontol. 2008; 79: 1950-1961.

[14]          Greenstein G, Tonetti M. The role of controlled drug delivery for periodontitis. The Research, Science and Therapy Committee of the American Academy of Periodontology. J Periodontol. 2000; 71: 125-140.

[15]          Sharma A, Pradeep AR. Clinical efficacy of 1% alendronate gel as a local drug delivery system in the treatment of chronic periodontitis: a randomized, controlled clinical trial. J Periodontol. 2012; 83: 11-18.

[16]          Khajuria DK, Zahra SF, Razdan R. Effect of locally administered novel biodegradable chitosan based risedronate/ zinc-hydroxyapatite intra-pocket dental film on alveolar bone density in rat model of periodontitis. J Biomater Sci Polym Ed. 2018; 29: 74-91.

[17]          Aghayan SH, Asghari A, Mortazavi P, Ghashghai SH. Histomorphometric Comparison of 2 types of FDBA and DFDBA bone powders manufactured by Hamanand Saz Baft Kish Company in treatment of defects in rabbit calvaria bone. J Res Dent Sci. 2019; 16: 1-12.